These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 1506154)

  • 1. Efficacy of gadoteridol for magnetic resonance imaging of extracranial head and neck pathology.
    Zoarski GH; Parker JR; Lufkin RB; Harnsberger HR; Rhoda CH
    Invest Radiol; 1992 Aug; 27 Suppl 1():S53-7. PubMed ID: 1506154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of gadoteridol for contrast-enhanced magnetic resonance imaging in children.
    Ball WS; Parker JR; Davis PC; Glasier CM; Morris MR
    Invest Radiol; 1992 Aug; 27 Suppl 1():S45-52. PubMed ID: 1506153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of gadoteridol for magnetic resonance imaging of the brain and spine.
    Runge VM; Bronen RA; Davis KR
    Invest Radiol; 1992 Aug; 27 Suppl 1():S22-32. PubMed ID: 1506150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II clinical trial of gadoteridol injection, a low-osmolal magnetic resonance imaging contrast agent.
    Carvlin MJ; De Simone DN; Meeks MJ
    Invest Radiol; 1992 Aug; 27 Suppl 1():S16-21. PubMed ID: 1506148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Magnetic resonance evaluation of brain metastases from systemic malignances with two doses of gadobutrol 1.0 m compared with gadoteridol: a multicenter, phase ii/iii study in patients with known or suspected brain metastases.
    Katakami N; Inaba Y; Sugata S; Tsurusaki M; Itoh T; Machida T; Tanaka H; Nakayama T; Morikawa T; Breuer J; Aitoku Y
    Invest Radiol; 2011 Jul; 46(7):411-8. PubMed ID: 21467949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase III clinical studies with gadoteridol for the evaluation of neurologic pathology. A European perspective.
    Seiderer M
    Invest Radiol; 1992 Aug; 27 Suppl 1():S33-8. PubMed ID: 1506151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multicenter trial of gadoteridol, a nonionic gadolinium chelate, in patients with suspected head and neck pathology.
    Zoarski GH; Lufkin RB; Bradley WG; Flanders AE; Gale DR; Harms SE; Haughton VM; Joy SE; Kanal E; Rosa L
    AJNR Am J Neuroradiol; 1993; 14(4):955-61. PubMed ID: 8352170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Indications for gadolinium-DTPA in magnetic resonance evaluation of extracranial head and neck mass lesions: review of experience with 27 patients examined with a 2 tesla imager.
    Chisin R; Gomori JM; Elidan J
    Isr J Med Sci; 1992; 28(3-4):268-76. PubMed ID: 1592599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase III multicenter clinical investigation to determine the safety and efficacy of gadoteridol in children suspected of having neurologic disease.
    Ball WS; Nadel SN; Zimmerman RA; Byrd SE; Dietrich RB; Prenger EC; Drayer BP; Nelson MD; Morgan FW; Altman NR
    Radiology; 1993 Mar; 186(3):769-74. PubMed ID: 8430186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical safety and efficacy of gadoteridol: a study in 411 patients with suspected intracranial and spinal disease.
    Runge VM; Bradley WG; Brant-Zawadzki MN; Carvlin MJ; DeSimone DN; Dean BL; Dillon WP; Drayer BP; Flanders AE; Harms SE
    Radiology; 1991 Dec; 181(3):701-9. PubMed ID: 1947085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MR arthrography of the glenohumeral joint: two concentrations of gadoteridol versus Ringer solution as the intraarticular contrast material.
    Binkert CA; Zanetti M; Gerber C; Hodler J
    Radiology; 2001 Jul; 220(1):219-24. PubMed ID: 11426001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review of the use of high-dose gadoteridol in the magnetic resonance evaluation of central nervous system tumors.
    Yuh WT; Fisher DJ; Mayr-Yuh NA; Tali ET; Nguyen HD; Gao F; Ehrhardt JC
    Invest Radiol; 1992 Aug; 27 Suppl 1():S39-44. PubMed ID: 1506152
    [No Abstract]   [Full Text] [Related]  

  • 13. Contrast enhancement of the inner ear after intravenous administration of a standard or double dose of gadolinium contrast agents.
    Suzuki H; Teranishi M; Sone M; Yamazaki M; Naganawa S; Nakashima T
    Acta Otolaryngol; 2011 Oct; 131(10):1025-31. PubMed ID: 21732744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Enhanced MR imaging with a nonionic contrast gadolinium complex, Gadoteridol, for lumbar disc herniation].
    Nakashima A; Nakashima K; Sugawara Y; Kawamura K
    Nihon Igaku Hoshasen Gakkai Zasshi; 1998 Apr; 58(5):221-5. PubMed ID: 9617157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Magnetic resonance imaging contrast agents.
    Runge VM
    Curr Opin Radiol; 1992 Feb; 4(1):3-12. PubMed ID: 1739599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Brain magnetic resonance with magnetization transfer in multiple sclerosis. Lesion hyperintensity before and after intravenous gadolinium administration].
    Renzetti P; Parodi RC; Losacco C; Rosso E; Arcuri T; Sardanelli F
    Radiol Med; 1999 Sep; 98(3):138-43. PubMed ID: 10575442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The initial clinical experiences with a dynamic FLASH-2D sequence in tumors of the head and neck area].
    Mäurer J; Hellwig A; Matthaei D; Carduck HP
    Rofo; 1993 May; 158(5):451-5. PubMed ID: 8490154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of 1.0 M gadobutrol and 0.5 M gadopentetate dimeglumine-enhanced magnetic resonance imaging in five hundred seventy-two patients with known or suspected liver lesions: results of a multicenter, double-blind, interindividual, randomized clinical phase-III trial.
    Hammerstingl R; Adam G; Ayuso JR; Van Beers B; Belfiore G; Bellin MF; Bongartz G; Ernst O; Frericks B; Giuseppetti G; Heinz-Peer G; Laghi A; Martin J; Pering C; Reimer P; Richter GM; Roemer FW; Schäfer FK; Vilgrain V; Vogl TJ; Weishaupt D; Wall A; Zech CJ; Tombach B
    Invest Radiol; 2009 Mar; 44(3):168-76. PubMed ID: 19169143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Difference in enhancement between spin echo and 3-dimensional fast spoiled gradient recalled acquisition in steady state magnetic resonance imaging of brain metastasis at 3-T magnetic resonance imaging.
    Furutani K; Harada M; Mawlan M; Nishitani H
    J Comput Assist Tomogr; 2008; 32(2):313-9. PubMed ID: 18379324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Oral contrast media for the magnetic resonance tomography of the abdomen. A clinical trial of the tolerance for gadolinium-DTPA].
    Kaminsky S; Laniado M; Gogoll M; Kornmesser W; Clauss W; Felix R
    Rofo; 1992 Jan; 156(1):17-23. PubMed ID: 1733470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.